John “Jay” Nichols Resigns as CEO of AXIS Re; Jan Ekberg Appointed Interim Head of Reinsurance
AXIS Capital Holdings Limited (“AXIS Capital”) (NYSE:AXS) announced today that John “Jay” Nichols has resigned his position as Chief Executive Officer of AXIS Re. Nichols has agreed to remain with the Company in a transitional role until March 31. The Company has named Jan Ekberg to succeed Nichols as Interim CEO of AXIS Re. Mr. Ekberg, who has been with the Company since 2004, currently serves as President and Chief Underwriting Officer of AXIS Re Europe and will report directly to AXIS Capital President and Chief Executive Officer Albert Benchimol.
“On behalf of AXIS, we would like to thank Jay for all he has done for our company. When Jay joined AXIS, we introduced a plan to strengthen our reinsurance business and broaden our risk-funding sources through high-quality partnerships,” said Mr. Benchimol. “Over the past five years we have made significant progress and AXIS Re is a global reinsurance leader, well-positioned against the backdrop of a structural shift in the reinsurance industry. We have also established AXIS as a strategic partner to respected third party capital providers. With this solid foundation in place, Jay has decided that he would like to leave to take on new challenges. We are deeply appreciative of Jay’s leadership and wish him the absolute best.”
“When I joined AXIS Re, we set a plan to profitably grow the reinsurance business, improve our analytical capabilities and expand into strategic capital partnerships to match the right risk with the right capital. I am grateful for what we have accomplished in all areas of the reinsurance business and I have been honored to lead such a talented and committed group for the past five years,” said Nichols. “I’ve very deeply enjoyed working with my team, my colleagues across AXIS, and being a part of the Company’s leadership. While there is still more work to be done, now is a good time for a transition and I leave with the confidence that AXIS Re is well-positioned to succeed and in very capable hands.”
Mr. Ekberg has more than 40 years of (re)insurance industry experience with more than 20 of these years managing underwriting businesses. He joined AXIS Re Europe in 2004 shortly after its formation and has been integral to establishing AXIS Re Europe as a leading international reinsurer. In his current position, Mr. Ekberg serves as President and Chief Underwriting Officer of AXIS Re Europe. During his tenure at AXIS, he has led the Property Risk team and the Engineering team. Before joining AXIS, Mr. Ekberg served in various underwriting and management positions at Nordisk Re in Copenhagen, Employers Re and GE Frankona in Munich. He spent the first nine years of his career in primary insurance.
About AXIS Capital
AXIS Capital is a Bermuda-based global provider of specialty lines insurance and treaty reinsurance with shareholders’ equity at December 31, 2016 of $6.3 billion and locations in Bermuda, the United States, Europe, Singapore, Middle East, Canada and Latin America. Its operating subsidiaries have been assigned a rating of “A+” (“Strong”) by Standard & Poor’s and “A+” (“Superior”) by A.M. Best. For more information about AXIS Capital, visit our website at www.axiscapital.com . Please be sure to follow AXIS Capital on LinkedIn .
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
ASTRAZENECA10.12.2017 23:47 | pressemeddelelse
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials
NJ-CELGENE/BLUEBIRD-BIO10.12.2017 16:32 | pressemeddelelse
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
GA-GILEAD-SCIENCES/KITE10.12.2017 16:32 | pressemeddelelse
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
MA-TAKEDA/SEATTLE10.12.2017 14:02 | pressemeddelelse
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
ASTRAZENECA9.12.2017 19:02 | pressemeddelelse
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial
JANSSEN9.12.2017 18:21 | pressemeddelelse
Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum